Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Cybulla

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Annals of the New York Academy of Sciences|November 15, 2006
Genetic and clinical investigation of pheochromocytoma: a 22-year experience, from Freiburg, Germany to international effortBirke Bausch, Carsten C Boedeker, Ansgar Berlis, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|March 9, 2026
Impact of SGLT2 inhibitors in patients with Fabry diseaseMalte Lenders, Sima Canaan-Kühl, Christine Kurschat, et al.
Journal of the American Society of Nephrology : JASN|November 3, 2018
Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry DiseaseMalte Lenders, Leon Paul Neußer, Michael Rudnicki, et al.
Neurological Research and Practice|December 16, 2025
Impact of migalastat on cerebral outcomes in fabry disease - results from the prospective observational FAMOUS trialMomoko Choudhury, Malte Lenders, Pauline Laufer, et al.
Plos One|May 22, 2013
Dysregulated autophagy contributes to podocyte damage in Fabry's diseaseMax C Liebau, Fabian Braun, Katja Höpker, et al.
International Urology and Nephrology|February 28, 2012
Adult patients with sporadic polycystic kidney disease: the importance of screening for mutations in the PKD1 and PKD2 genesHartmut P H Neumann, Janina Bacher, Zinaida Nabulsi, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 10, 2013
Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western GermanyHartmut P H Neumann, Cordula Jilg, Janina Bacher, et al.
Clinical Pharmacology and Therapeutics|March 22, 2020
Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS)Malte Lenders, Peter Nordbeck, Christine Kurschat, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 5, 2022
Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS)Malte Lenders, Peter Nordbeck, Christine Kurschat, et al.
JAMA|October 27, 2005
Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC geneFrancesca Schiavi, Carsten C Boedeker, Birke Bausch, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Annals of the New York Academy of Sciences|November 15, 2006
Genetic and clinical investigation of pheochromocytoma: a 22-year experience, from Freiburg, Germany to international effortBirke Bausch, Carsten C Boedeker, Ansgar Berlis, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|March 9, 2026
Impact of SGLT2 inhibitors in patients with Fabry diseaseMalte Lenders, Sima Canaan-Kühl, Christine Kurschat, et al.
Journal of the American Society of Nephrology : JASN|November 3, 2018
Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry DiseaseMalte Lenders, Leon Paul Neußer, Michael Rudnicki, et al.
Neurological Research and Practice|December 16, 2025
Impact of migalastat on cerebral outcomes in fabry disease - results from the prospective observational FAMOUS trialMomoko Choudhury, Malte Lenders, Pauline Laufer, et al.
Plos One|May 22, 2013
Dysregulated autophagy contributes to podocyte damage in Fabry's diseaseMax C Liebau, Fabian Braun, Katja Höpker, et al.
International Urology and Nephrology|February 28, 2012
Adult patients with sporadic polycystic kidney disease: the importance of screening for mutations in the PKD1 and PKD2 genesHartmut P H Neumann, Janina Bacher, Zinaida Nabulsi, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 10, 2013
Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western GermanyHartmut P H Neumann, Cordula Jilg, Janina Bacher, et al.
Clinical Pharmacology and Therapeutics|March 22, 2020
Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS)Malte Lenders, Peter Nordbeck, Christine Kurschat, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 5, 2022
Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS)Malte Lenders, Peter Nordbeck, Christine Kurschat, et al.
JAMA|October 27, 2005
Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC geneFrancesca Schiavi, Carsten C Boedeker, Birke Bausch, et al.
Pageof 3